A) Reduced bleeding at the cost of increased ischemic eventsB) Reduced bleeding without an increase in ischemic eventsC) Increased ischemic events with no change in major bleeding eventsD) No significant difference in outcomes
A) Decreased all-cause mortalityB) Decreased risk of heart failureC) No significant difference in all-cause mortality or future AMID) Decreased risk of future MI
A) BedtimeB) MorningC) Divided doses are preferred regardlessD) No difference—patients should take it at the time that best suits their schedule and routine.
A) No significant change in cardiotoxicityB) Terminated prematurely due to futilityC) Significant reduction in the incidence of cardiotoxicityD) Terminated prematurely due to significant adverse effects
A) TAVI was non-inferior to SAVR in terms of the primary outcomeB) Higher rate of atrial fibrillation compared to SAVRC) Higher all-cause mortality compared to SAVRD) Higher rate of major bleeding compared to SAVR
A) Increased reduction in all-cause mortalityB) No significant difference in the composite outcome of death, non-fatal MI, stroke, and CV hospitalization compared to continuationC) Increase in nonfatal myocardial infarctionsD) Increased recurrent ischemic events
A) OCT-guided PCI resulted in a lower incidence of major adverse cardiac events (MACE).B) There was no difference in MACE between the two groups.C) Stroke and bleeding events were more prevalent in the angiography-guided PCI group.D) OCT-guided PCI was associated with less contrast use and shorter procedural duration.
A) To evaluate the efficacy of edoxaban added to aspirin in patients with high-risk stable anginaB) To assess the safety and efficacy of edoxaban monotherapy compared with dual antithrombotic therapy in patients with high-risk atrial fibrillation and stable coronary artery diseaseC) To compare the outcomes of edoxaban with warfarin in patients with AF and CADD) To determine the optimal duration of dual antithrombotic therapy with edoxaban and aspirin in patients with atrial fibrillation and coronary artery disease
A) There was no difference in bleeding events between the TAVI-alone and TAVI-plus-PCI groups.B) The primary endpoint of the trial was a reduction in disabling stroke.C) TAVI plus PCI resulted in a significant reduction in the composite outcome of death from any cause, MI, or urgent revascularization.D) The results suggest avoiding PCI in TAVI patients.
A) Continuing RASIs before major non-cardiac surgery significantly reduces post-operative complications.B) There was no significant difference in the rates of major post-operative complications between continuation and discontinuation of RASIs.C) Episodes of hypotension during surgery were more frequent in the continuation group and led to more complications.D) The results suggest discontinuing RASIs before surgery in all patients.
A) Mitral transcatheter edge-to-edge repair (M-TEER) significantly reduced cardiovascular death and HF-related hospitalizations compared to optimal medical therapy alone.B) Patients receiving M-TEER showed improved health status, as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) overall score.C) The M-TEER procedure was associated with no significant safety concerns.D) M-TEER was found to be less effective than optimal medical therapy alone in reducing symptoms of heart failure.
A) Reduced hospital stayB) Reduced cardiovascular eventsC) Improved exercise capacityD) No benefit was observed; instead, more major complications occurred.
A) Continuing OACs significantly reduced thromboembolic events compared to interrupting them before TAVI but at the expense of increased bleeding.B) Interrupting OACs before TAVI increased the risk of stroke but not MI.C) Continuing OACs provided no significant benefit in reducing thromboembolic events compared to interrupting them.D) Interrupting OACs before TAVI led to a significantly lower incidence of bleeding complications but a higher risk of stroke and MI.
A) Finerenone significantly reduced the composite rate of worsening heart failure events and cardiovascular death compared to placebo.B) The reduction in heart failure events and cardiovascular death was similar in both women and men.C) Finerenone was well tolerated, with a safety profile comparable to placebo.D) All of the above.
A) Semaglutide was not safe enough for patients with chronic kidney disease.B) Semaglutide had no effect on heart failure outcomes in patients with diabetes and CKD.C) Semaglutide was safe and effective in reducing death from cardiovascular causes in patients with diabetes and CKD.D) Semaglutide was safe in patients with diabetes and CKD but had a neutral effect on cardiovascular events.
A) Significant reduction in cardiovascular deathB) Significant reduction in recurrent myocardial infarctionC) Significant reduction in revascularizationD) No significant reduction in major adverse cardiovascular events
A) Tirzepatide significantly reduced the combined risk of worsening heart failure events and cardiovascular death compared to placebo.B) Patients treated with tirzepatide showed significant improvements in health status, as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ).C) Tirzepatide failed to increase exercise tolerance, as measured by the 6-minute walk distance (6MWD).D) Tirzepatide led to a greater reduction in body weight and high-sensitivity C-reactive protein compared to placebo.
A) Adding metformin significantly reduced AF burden or progression compared to standard care.B) Diet and exercise counseling did not significantly improve AF symptom scores.C) Even the standard care group, which received educational materials on healthy lifestyle, saw decreases in AF burden over time.D) There were safety concerns about the use of metformin in the study population.
A) Muvalaplin significantly reduced Lp(a) levels by up to 85.8%.B) The reductions in Lp(a) levels were dose-dependent, with the highest dose (240 mg) showing the greatest reduction.C) Muvalaplin was well tolerated, with no significant safety or tolerability concerns reported.D) All of the above.
A) Sacubitril/valsartan significantly reduced the risk of cardiotoxicity compared to placebo.B) The sacubitril/valsartan group did not show any improvement in global longitudinal strain (GLS).C) The safety profile of sacubitril/valsartan was worse than placebo.D) The study was terminated due to safety concerns in the treatment arm, and the benefit was neutral.
This Quiz is sponsored by
